Tamsulosin Hydrochloride
Product Images NDC 58118-0030

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 58118-0030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ab8b786d-figure-01 (Ab8b786d Figure 01)

Chemical structure of tamsulosin hydrochloride, showing its molecular framework including aromatic rings, methoxy groups, an ethoxy group, and a sulfonamide moiety with an attached hydrochloride.*

FDA Label Image

Ab8b786d-figure-02 (Ab8b786d Figure 02)

A plasma concentration-time graph showing Tamsulosin hydrochloride levels (ng/mL) over 36 hours. Two lines compare plasma concentration under fasted and fed conditions, with plasma concentration on the y-axis and time in hours on the x-axis.*

FDA Label Image

Ab8b786d-figure-03 (Ab8b786d Figure 03)

A line chart depicting mean change over treatment duration in weeks for three groups: Tamsulosin hydrochloride 0.8 mg, 0.4 mg, and placebo. The x-axis represents duration from baseline to 13 weeks, and the y-axis shows mean change values. Each treatment group's progression is plotted with distinct markers and lines.*

FDA Label Image

Ab8b786d-figure-04 (Ab8b786d Figure 04)

A line graph depicting the mean change over the duration of treatment in weeks for three groups: 0.8 mg, 0.4 mg doses, and placebo. The x-axis represents treatment duration from 0 to 13 weeks plus last observation carried forward (LOCF), with sample sizes noted. The y-axis shows mean change values from 0 to -11. Each treatment group shows a trend of decreasing mean values over time, with 0.8 mg and 0.4 mg generally lower than placebo toward later weeks.*

FDA Label Image

Ab8b786d-figure-05 (Ab8b786d Figure 05)

A line graph depicting mean change in mL/sec over treatment duration weeks for Tamsulosin hydrochloride at doses 0.8 mg and 0.4 mg compared to placebo. The graph shows higher mean change values for both 0.8 mg and 0.4 mg treatments versus placebo throughout the treatment period, with data points at multiple weeks and last observation carried forward (LOCF).*

FDA Label Image

Ab8b786d-figure-06 (Ab8b786d Figure 06)

A line graph showing mean change in mL/sec over duration of treatment in weeks for Tamsulosin hydrochloride clinical study arms. Three treatment groups are compared: 0.8 mg, 0.4 mg, and placebo. The mean change is plotted over 0, 1, 2, 5, 9, 13 weeks and last observation carried forward (LOCF). Both Tamsulosin doses show greater improvement than placebo, with 0.8 mg consistently highest, peaking sharply around 2 weeks then stabilizing.*

FDA Label Image

Tamsulosin HCl 0.4mg Capsule 30 Count Blister Card (Ab8b786d Figure 07)

Label for Tamsulosin hydrochloride 0.4 mg capsules by Clinical Solutions Wholesale, showing NDC 58118-0030-8. The label includes manufacturing details by Actavis Pharma, Inc., package quantity of 30 capsules, and distributor information from Clinical Solutions Wholesale, Franklin, TN.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.